Marc A Schneider
Overview
Explore the profile of Marc A Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Yaung S, Woestmann C, Ju C, Ma X, Gattam S, Zhou Y, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626082
Monitoring treatment efficacy early during therapy could enable a change in treatment to improve patient outcomes. We report an early assessment of response to treatment in advanced NSCLC using a...
22.
Buhler L, Enderle M, Kahn N, Polke M, Schneider M, Heussel C, et al.
Biomedicines
. 2022 May;
10(5).
PMID: 35625838
(1) Development of radiofrequency ablation (RFA) systems for pulmonary lesions is restricted by availability of human tumor specimens and limited comparability of animal tissue. We aimed to develop a new...
23.
Salgueiro L, Kummer S, Sonntag-Buck V, Weiss A, Schneider M, Krausslich H, et al.
J Virol
. 2022 Mar;
96(7):e0009822.
PMID: 35285684
Respiratory viruses cause mild to severe diseases in humans every year, constituting a major public health problem. Characterizing the pathogenesis in physiologically relevant models is crucial for developing efficient vaccines...
24.
Schneider M, Richtmann S, Grunding A, Wrenger S, Welte T, Meister M, et al.
Int J Oncol
. 2022 Feb;
60(4).
PMID: 35211754
Transmembrane serine protease 2 (TMPRSS2) has been intensively investigated during the current Sars‑CoV‑2 pandemic as a virus activating protease. Furthermore, is an oncogenic gene associated with several cancer entities. Co‑expression...
25.
Schneider M, Rozy A, Wrenger S, Christopoulos P, Muley T, Thomas M, et al.
Front Oncol
. 2022 Feb;
12:772076.
PMID: 35174082
In the last decade, targeting the immune system became a promising therapy in advanced lung cancer stages. However, in a clinical follow-up, patient responses to immune checkpoint inhibitors widely differ....
26.
Angeles A, Christopoulos P, Yuan Z, Bauer S, Janke F, Ogrodnik S, et al.
NPJ Precis Oncol
. 2021 Dec;
5(1):100.
PMID: 34876698
Targeted kinase inhibitors improve the prognosis of lung cancer patients with ALK alterations (ALK+). However, due to the emergence of acquired resistance and varied clinical trajectories, early detection of disease...
27.
Fisch D, Bozorgmehr F, Kazdal D, Kuon J, Klotz L, Shah R, et al.
Front Oncol
. 2021 Jul;
11:673901.
PMID: 34307143
Background: Large-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options. Methods: We retrospectively analyzed all patients with metastatic LCNEC in the records...
28.
Christopoulos P, Bozorgmehr F, Bruckner L, Chung I, Krisam J, Schneider M, et al.
BMC Cancer
. 2021 Jun;
21(1):743.
PMID: 34182952
Background: Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK non-smallcell lung cancer (NSCLC) patients to over five years. In particular,...
29.
Goldmann T, Schmitt B, Muller J, Kroger M, Scheufele S, Marwitz S, et al.
Clin Epigenetics
. 2021 Feb;
13(1):38.
PMID: 33596996
Background: Lung cancer is the leading cause of cancer-related death in most western countries in both, males and females, accounting for roughly 20-25% of all cancer deaths. For choosing the...
30.
Eichhorn F, Klotz L, Kriegsmann M, Bischoff H, Schneider M, Muley T, et al.
Lung Cancer
. 2021 Feb;
153:150-157.
PMID: 33529989
Objectives: A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery for the treatment of non-small cell...